解放军医学杂志2023，Vol.48Issue(12)：1359-1369,11.DOI:10.11855/j.issn.0577-7402.1079.2023.1103
重症患者凝血酶原复合物合理应用中国专家共识
Chinese expert consensus on the rational use of prothrombin complex concentrate in critically ill patients
宋景春 1中国医药教育协会血栓与止血危重病专业委员会 2全军重症医学专业委员会 2中国研究型医院学会血栓与止血专业委员会 2王岗 3房云海 4吴海鹰 5尹海燕 6张进华 7柯路 8丁仁彧 9周洲10
作者信息
- 1. 解放军联勤保障部队第908医院重症医学科,江西南昌 330002
- 3. 西安交通大学第二附属医院重症医学科,陕西西安 710004
- 4. 山东省血液中心血友病诊疗中心,山东济南 250013
- 5. 昆明医科大学第一附属医院急诊科,云南昆明 650032
- 6. 暨南大学附属第一医院重症医学科,广东广州 510630
- 7. 福建省妇幼保健院药学科,福建福州 350005
- 8. 东部战区总医院重症医学科,江苏南京 210002
- 9. 中国医科大学附属第一医院重症医学科,辽宁沈阳 110001
- 10. 中国医学科学院阜外医院检验科,北京 100037
- 折叠
摘要
Abstract
The prothrombin complex concentrate(PCC)is a blood product that mainly contains vitamin K-dependent coagulation factors.PCC has been used clinically for more than 70 years,and its safety has been significantly improved.It has been widely used in the treatment of coagulation disorders or severe bleeding in critically ill patients.If used improperly,it may weaken the hemostatic effect or increase the risk of thrombosis.In order to standardize the rational use of PCC,Chinese Society of Thrombosis,Hemostasis and Critical Care,Chinese Medicine Education Association,People's Liberation Army Professional Committee of Critical Care Medicine,Chinese Society of Thrombosis and Hemostasis,Chinese Research Hospital Association have organized the formulation of this expert consensus,including three parts:definition,indications,and monitoring and evaluation of efficacy,with a total of 10 suggestions,aiming to help clinicians reasonably use PCC and improve the treatment in critical illness.关键词
凝血酶原复合物/血液凝固因子/危重病/出血Key words
prothrombin complex concentrate/blood coagulation factors/critical illness/hemorrhage分类
医药卫生引用本文复制引用
宋景春,中国医药教育协会血栓与止血危重病专业委员会,全军重症医学专业委员会,中国研究型医院学会血栓与止血专业委员会,王岗,房云海,吴海鹰,尹海燕,张进华,柯路,丁仁彧,周洲..重症患者凝血酶原复合物合理应用中国专家共识[J].解放军医学杂志,2023,48(12):1359-1369,11.
